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TEX Are a Discrete T Cell Subset
T cell exhaustion is a distinct differentiation state that can be distinguished from naive, effector, and memory T cells. Compared to effector (TE) and memory (TMEM) T cells, 
exhausted T cells (TEX) display impaired effector functions (e.g., rapid production of effector cytokines, cytotoxicity) (Wherry and Kurachi, 2015). TEX have limited proliferative 
potential, especially compared to some subsets of TMEM (e.g., TSCM and TCM) and naive T cells (TN). TEX also develop a distinct transcriptional program that is unlike TN, TE, or TMEM 
(Doering et al., 2012; Martinez et al., 2015; Paley et al., 2012), a feature shared between chronic infections and cancer (Baitsch et al., 2011). TEX confer only weak or temporary 
immune pressure on chronic infections or tumors, and this immunity is ultimately ineffective (Wherry and Kurachi, 2015). TEX can be re-invigorated by blockade of PD-1 and 
other inhibitory receptors and immunoregulatory pathways (Barber et al., 2006; Wherry and Kurachi, 2015). This re-invigoration demonstrates that at least a subset of TEX retains 
residual protective potential and has been translated into impressive clinical results in cancer (Page et al., 2014). Exhaustion can develop in both CD4+ and CD8+ T cells, though 
CD8+ T cell exhaustion is better understood and is the focus of this Snapshot.
Origins of Exhaustion
Unlike other forms of T cell dysfunction (e.g., anergy), exhaustion is not induced at priming (Wherry and Kurachi, 2015). Longitudinal analyses support the notion of gradual 
induction of dysfunction. For example, the transcriptional profi les of virus-specifi c CD8+ T cells during an acutely resolving versus developing chronic viral infection are largely 
similar at days 6 and 8 post-infection (p.i.). At day 15 p.i., these transcriptional programs diverge toward memory or exhaustion (Doering et al., 2012; Wherry and Kurachi, 2015). 
Moreover, CD8+ T cells primed during a chronic infection can develop into functional TMEM if removed from the chronic infection at day 8 p.i., but not day 15 or 30 p.i. (Angelosanto 
et al., 2012; Brooks et al., 2006). TEX and TMEM also both develop from the CD127
+KLRG1 “memory precursor” subset of TE, indicating a common developmental origin for TEX and 
TMEM (Angelosanto et al., 2012).
Signals for the Development of TEX
While the development of TEX remains incompletely understood, persisting and likely continuous rather than intermittent antigen stimulation appears to be a key signal driving 
exhaustion. However, other types of signals are also likely important. These include: proinfl ammatory (e.g., IFN-/, IL-6, IL-27) and suppressive (e.g., IL-10, TGF-) cytokines, 
other regulatory leukocytes (e.g., regulatory T cells, immunoregulatory antigen presenting cells), and the tissue microenvironment (e.g., altered hypoxia, nutrients, pH) (Wherry 
and Kurachi, 2015). Together with chronic TCR engagement, these signals drive elevated and sustained expression of multiple inhibitory receptors (e.g., PD-1, Lag-3, Tim-3, etc.), 
altered use of key transcription factors (e.g., T-bet, Eomes, Blimp-1, NFAT/AP-1), changes in metabolism, and a transcriptional program distinct from other T cell differentiation 
states. Ultimately, these signals lead to progressive loss of effector functions, altered homeostasis compared to TMEM, and cell death due to overstimulation. As a result, T cell 
exhaustion results in poor control of pathogens or tumors. However, the ability to partially reverse exhaustion through strategies including PD-1 pathway blockade suggests that 
TEX, or at least a subset of this pool, are not terminally differentiated and can contribute to protective immunity if re-invigorated.
Subsets of TEX
At least two subsets of TEX exist based on expression of PD-1 and the T-box transcription factors T-bet and Eomesodermin (Eomes) (Blackburn et al., 2008; Paley et al., 2012). 
One subset expresses high T-bet and intermediate PD-1 (T-bethi PD-1int), whereas the other subset expresses high Eomes and high PD-1 but lower T-bet (Eomeshi PD-1hi). These 
two subsets differ in key functions. The T-bethi PD-1int subset retains moderate proliferative capacity and some potential to produce effector cytokines (e.g., IFN, TNF) but has 
limited cytotoxicity. The Eomeshi PD-1hi subset produces less cytokines and has poor proliferative potential but retains partial cytotoxicity compared to the T-bethi PD-1int subset 
(Paley et al., 2012). Only the T-bethi PD-1int subset can be reinvigorated by PD-1:PD-L1 pathway blockade, an observation with implications for immunotherapy (Blackburn et al., 
2008). A lineage relationship exists between these two subsets: the T-bethi PD-1int subset divides in response to persisting antigen, giving rise to Eomeshi PD-1hi progeny. The 
Eomeshi PD-1hi cells are terminally differentiated and do not convert back to T-bethi PD-1int cells (Paley et al., 2012). Thus, the T-bethi PD-1int cells are referred to as the “progenitor 
subset” and the Eomeshi PD-1hi as the “terminal subset.”
TEX Based on Anatomical Location
There is likely additional heterogeneity in the pool of TEX based on tissue location and disease context. In chronic infection, the T-bet
hi progenitor subset is found in the spleen 
and blood, while the Eomeshi PD-1hi terminal subset is more abundant in non-lymphoid tissues (Paley et al., 2012) and possibly tumors. However, the distinct microenvironments 
of non-lymphoid tissues and tumors are likely to infl uence TEX biology. Indeed, different tissues have different ratios of T-bet
hi to Eomeshi subsets, and TEX in these locations may 
differ in other key phenotypic and functional attributes (Blackburn et al., 2008; Paley et al., 2012). Therefore, while TEX represents a discrete differentiation state compared to TN, 
TE, and TMEM, the disease context and location may impart additional layers of heterogeneity.
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